U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H8I3N2O4.Na
Molecular Weight 635.8954
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIATRIZOATE SODIUM

SMILES

[Na+].CC(=O)NC1=C(I)C(C([O-])=O)=C(I)C(NC(C)=O)=C1I

InChI

InChIKey=ZEYOIOAKZLALAP-UHFFFAOYSA-M
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C11H8I3N2O4
Molecular Weight 612.9056
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf

This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.

Originator

Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Cystografin

Approved Use

Retrograde cystourethrography

Launch Date

1955
Diagnostic
Gastrografin

Approved Use

Gastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon).

Launch Date

1958
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7 mg/mL
7.2 mg/kg single, intravenous
dose: 7.2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROGEN IODIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.6 mg/mL
3.36 mg/kg single, intravenous
dose: 3.36 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROGEN IODIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
102 min
7.2 mg/kg single, intravenous
dose: 7.2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROGEN IODIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
110 min
3.36 mg/kg single, intravenous
dose: 3.36 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROGEN IODIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors.
2002-12
Rectal washout with cytotoxic solution can be extended to the whole colon.
2002-12
Evidence for involvement of mast cell degranulation and subsequent stimulation of histamine H1 and H2 receptors in radiographic contrast media-increased vascular permeability in rats.
2002-12
The role of theophylline in contrast-induced nephropathy: a case-control study.
2002-11
Pressure-assisted micturating cystourethrography: reduction in duration of procedure and fluoroscopy time.
2002-11
Thumbprinting due to ischemic colitis in a patient on oral anticoagulation.
2002-10-31
The value of contrast radiology for postoperative adhesive small bowel obstruction.
2002-10-26
Venous port salvage utilizing low dose tPA.
2002-10-23
Chronic renal dysfunction late after liver transplantation.
2002-10
Iodinated contrast medium-induced potassium release: the effect of mixing ratios.
2002-09-26
[Fast method of labelling leukocytes with 99mTc HM PAO].
2002-09-19
[Ultrasound and X-ray urethrography and urethroscopy during endoscopic operations on the urethra].
2002-09-10
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model.
2002-09
The diagnostic yield of colonoscopy and the therapeutic value of intraduodenal amidotrizoic acid injection in intestinal Diphyllobothrium latum infection: report of a case.
2002-09
Ex vivo expansion of megakaryocyte progenitors from cryopreserved umbilical cord blood. A potential source of megakaryocytes for transplantation.
2002-09
Is same-day sonography of the gallbladder feasible after intravenous urography or contrast-enhanced computed tomography?
2002-09
Iothalamate measured by capillary electrophoresis is a suitable alternative to radiolabeled inulin in renal micropuncture.
2002-09
Type IV diaphragmatic hiatal hernia.
2002-08-03
Diagnosis and management of enterovesical fistulas in patients with Crohn's disease.
2002-08
Electrocardiographic effects of diagnostic imaging agents.
2002-08
Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress.
2002-08
Application of oral contrast media in coregistered positron emission tomography-CT.
2002-08
Emergency colonoscopy for distal intestinal obstruction syndrome in cystic fibrosis patients.
2002-08
Effects of intrathecal injection of diatrizoate on dopamine receptors.
2002-07
Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease.
2002-07
Contrast radiography and intestinal obstruction.
2002-07
Therapeutic value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a prospective randomized trial.
2002-07
Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media.
2002-07
Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass.
2002-05-23
Aneurysmal bone cysts: treatment with direct percutaneous Ethibloc injection: long-term results.
2002-05-23
Jejunum free flap in hypopharynx reconstruction: case series.
2002-05-10
A case of gastric duplication evaluated by gastric emptying scintigraphy.
2002-05
Long-term survival of patients with stage IV hypopharyngeal cancer: impact of fundus rotation gastroplasty.
2002-05
New strategies in nonoperative management of meconium ileus.
2002-05
Renal excretion of ingested gastrografin: clinical relevance in early postoperative treatment of patients who have undergone gastric surgery.
2002-05
[Which imaging in case of sigmoid diverticulitis? The value of ultrasound (Conventional B-mode in combination with hydrocolonsonography and colour flow Doppler) in comparison to the well-established modalities like contrast enema and helical computertomography].
2002-04
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus.
2002-04
Gastrografin administration in the treatment of postoperative delayed gastric emptying.
2002-04
Effect of iomeprol on rat hippocampal slice synaptic transmission: comparison with other X-ray contrast agents.
2002-04
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis?
2002-03-01
Early esophageal transit study after laparoscopic fundoplication: how useful is it?
2002-03
Gastrocolocutaneous Fistula as a complication of peg tube placement.
2002-03
Changes in the fibrinolytic system during angiography with ionic and with nonionic contrast media.
2002-03
Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial.
2002-03
Primary anastomosis and diverting colostomy in diffuse diverticular peritonitis.
2002-02
Virtual gastroduodenoscopy: a new look at the bypassed stomach and duodenum after laparoscopic Roux-en-Y gastric bypass for morbid obesity.
2002-02
The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass.
2002-02
[Opportunities of delayed densitometry of "late (fixed) contrast" as a test for tumors in residual mediastinal lesion in primary mediastinal lymphosarcoma after polychemotherapy].
2002
Ionic radiocontrast media disrupt intercellular contacts via an extracellular calcium-independent mechanism.
2002
An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
2001-12
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html ;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:45:31 GMT 2025
Edited
by admin
on Wed Apr 02 09:45:31 GMT 2025
Record UNII
V5403H8VG7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIATRIZOATE SODIUM
GREEN BOOK   ORANGE BOOK   USP   VANDF   WHO-IP  
Common Name English
SODIUM AMIDOTRIZOATE
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Preferred Name English
NSC-61815
Code English
RENOVIST COMPONENT DIATRIZOATE SODIUM
Common Name English
HYPAQUE SODIUM 20%
Brand Name English
DIATRIZOATE SODIUM [ORANGE BOOK]
Common Name English
DIATRIZOIC ACID SODIUM SALT
MI  
Common Name English
GASTROVIST COMPONENT DIATRIZOATE SODIUM
Common Name English
RENOGRAFIN COMPONENT DIATRIZOATE SODIUM
Common Name English
DIATRIZOIC ACID SODIUM SALT [MI]
Common Name English
NATRII AMIDOTRIZOAS [WHO-IP LATIN]
Common Name English
SODIUM AMIDOTRIZOATE [EP IMPURITY]
Common Name English
UROGRAPHING 370
Common Name English
TRIOMBRINE
Common Name English
sodium amidotrizoate [INN]
Common Name English
MEGLUMINE SODIUM AMIDOTRIZOATE INJECTION [JAN]
Common Name English
SODIUM AMIDOTRIZOATE [MART.]
Common Name English
MD-GASTROVIEW COMPONENT DIATRIZOATE SODIUM
Common Name English
UROVIST SODIUM
Brand Name English
DIATRIZOATE SODIUM [USP MONOGRAPH]
Common Name English
ANGIOVIST COMPONENT DIATRIZOATE SODIUM
Common Name English
SODIUM AMIDOTRIZOATE [WHO-IP]
Common Name English
DIATRIZOATE SODIUM [VANDF]
Common Name English
Monosodium 3,5-diacetamido-2,4,6-triiodobenzoate
Systematic Name English
RENOCAL COMPONENT DIATRIZOATE SODIUM
Common Name English
GASTROGRAFIN COMPONENT DIATRIZOATE SODIUM
Common Name English
BENZOIC ACID, 3,5-BIS(ACETYLAMINO)-2,4,6-TRIIODO-, MONOSODIUM SALT
Common Name English
DIATRIZOATE SODIUM [WHO-IP]
Common Name English
DIATRIZOATE SODIUM [GREEN BOOK]
Common Name English
SODIUM DIATRIZOATE
Common Name English
SODIUM AMIDOTRIZOATE [EP MONOGRAPH]
Common Name English
Sodium amidotrizoate [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C390
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
CFR 21 CFR 522.563
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
Code System Code Type Description
WIKIPEDIA
Diatrizoate
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
PUBCHEM
23672589
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
RXCUI
3321
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY RxNorm
DAILYMED
V5403H8VG7
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
MERCK INDEX
m4263
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID7022912
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
DRUG BANK
DBSALT000267
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
CAS
737-31-5
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
212-004-1
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
EVMPD
SUB10547MIG
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
NSC
61815
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIATRIZOATE SODIUM
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY Description: A white powder; odourless or almost odourless. Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Radiocontrast medium. Storage: Sodium amidotrizoate should be kept in a well-closed container, protected from light. Requirements: Sodium amidotrizoate contains not less than 98.0% and not more than the equivalent of 102.0% of C11H8I3N2NaO4, calculated with reference to the anhydrous substance.
FDA UNII
V5403H8VG7
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
SMS_ID
100000091989
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201220
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
NCI_THESAURUS
C47981
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
HSDB
8078
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
INN
358
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
CHEBI
53692
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
PRIMARY
CAS
24360-64-3
Created by admin on Wed Apr 02 09:45:31 GMT 2025 , Edited by admin on Wed Apr 02 09:45:31 GMT 2025
ALTERNATIVE
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
No peak value listed on EP
IMPURITY -> PARENT
No peak value listed in EP
Related Record Type Details
ACTIVE MOIETY